Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc., 49888-49889 [2022-17361]
Download as PDF
<![CDATA[
49888
Federal Register / Vol. 87, No. 155 / Friday, August 12, 2022 / Notices
purposes of this Investigation may be
disclosed to and used: (i) by the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
By order of the Commission.
Issued: August 8, 2022.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2022–17298 Filed 8–11–22; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1067]
Importer of Controlled Substances
Application: Cambridge Isotope
Laboratories, Inc.
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 18, 2022,
Cambridge Isotope Laboratories, 50
Frontage Road, Andover, Massachusetts
01810–5413, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
Controlled
substance
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Gamma Hydroxybutyric
Acid.
Tetrahydrocannabinols ..
Morphine ........................
Cambridge Isotope
Laboratories has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 12, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 12, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
Drug
code
Schedule
2010
I
7370
9300
I
II
jspears on DSK121TN23PROD with NOTICES
SUMMARY:
2 All
contract personnel will sign appropriate
nondisclosure agreements.
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
VerDate Sep<11>2014
17:38 Aug 11, 2022
Jkt 256001
The company plans to import the
listed controlled substances for
preparation of analytical standards and
formulations. In reference to drug codes
7370 (Tetrahydrocannabinols), the
company plans to import a synthetic
Tetrahydrocannabinol. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–17364 Filed 8–11–22; 8:45 am]
BILLING CODE P
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1065]
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Galephar Pharmaceutical
Research, Inc. has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 12, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 12, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 28, 2022, Galephar
Pharmaceutical Research, Inc., 100 Carr
198 Industrial Park, Juncos, Puerto Rico
00777–3873, applied to be registered as
DATES:
E:\FR\FM\12AUN1.SGM
12AUN1
Federal Register / Vol. 87, No. 155 / Friday, August 12, 2022 / Notices
an importer of the following basic
class(es) of controlled substance(s):
Controlled substance
Hydromorphone .............
Drug
code
9150
Schedule
II
The company plans to import the
listed controlled substance in finished
dosage form for analytical purpose only.
No other activity for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–17361 Filed 8–11–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF LABOR
Agency Information Collection
Activities; Formative Data Collections
for DOL Research
Notice of availability; request
for comments.
ACTION:
The Department of Labor
(DOL) is submitting this Chief
Evaluation Office (CEO)-sponsored
information collection request (ICR) to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (PRA). Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that the agency
receives on or before September 12,
2022.
SUMMARY:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Comments are invited on: (1) whether
the collection of information is
necessary for the proper performance of
the functions of the Department,
including whether the information will
have practical utility; (2) the accuracy of
the agency’s estimates of the burden and
cost of the collection of information,
jspears on DSK121TN23PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
17:38 Aug 11, 2022
Jkt 256001
including the validity of the
methodology and assumptions used; (3)
ways to enhance the quality, utility and
clarity of the information collection; and
(4) ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
automated collection techniques or
other forms of information technology.
FOR FURTHER INFORMATION CONTACT:
Nicole Bouchet by telephone at 202–
693–0213, or by email at DOL_PRA_
PUBLIC@dol.gov.
SUPPLEMENTARY INFORMATION: The Chief
Evaluation Office of DOL seeks approval
of this generic clearance to allow DOL
to conduct a variety of formative data
collections. Under this generic
clearance, DOL would engage in a
variety of formative data collections
with researchers, practitioners,
technical assistance providers, service
providers and potential participants
throughout the field to fulfill the
following goals: (1) inform the
development of DOL research, (2)
maintain a research agenda that is
rigorous and relevant, (3) ensure that
research products are as current as
possible and (4) inform the provision of
technical assistance. DOL envisions
using a variety of techniques including
semi-structured discussions, focus
groups, surveys, and telephone or inperson interviews in order to reach
these goals. The findings from this data
collection can inform and support
future and current research but that are
not highly systematic or intended to be
statistically representative or otherwise
generalizable. For additional substantive
information about this ICR, see the
related notice published in the Federal
Register on March 8, 2021 (86 FR
13401).
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless the OMB
approves it and displays a currently
valid OMB Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
display a valid OMB Control Number.
See 5 CFR 1320.5(a) and 1320.6.
DOL seeks PRA authorization for this
information collection for three (3)
years. OMB authorization for an ICR
cannot be for more than three (3) years
without renewal. The DOL notes that
information collection requirements
submitted to the OMB for existing ICRs
receive a month-to-month extension
while they undergo review.
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
49889
Agency: DOL–CEO.
Title of Collection: Formative Data
Collections for DOL Research.
OMB Control Number: 1290–0NEW.
Affected Public: Individuals or
Households.
Total Estimated Number of
Respondents: 5,500.
Total Estimated Number of
Responses: 5,500.
Total Estimated Annual Time Burden:
5,500 hours.
Total Estimated Annual Other Costs
Burden: $0.
(Authority: 44 U.S.C. 3507(a)(1)(D))
Nicole Bouchet,
Senior PRA Analyst.
[FR Doc. 2022–17335 Filed 8–11–22; 8:45 am]
BILLING CODE 4510–26–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
National Endowment for the
Humanities
Meeting of Humanities Panel
National Endowment for the
Humanities; National Foundation on the
Arts and the Humanities.
ACTION: Notice of meeting.
AGENCY:
The National Endowment for
the Humanities (NEH) will hold seven
meetings, by videoconference, of the
Humanities Panel, a federal advisory
committee, during September 2022. The
purpose of the meetings is for panel
review, discussion, evaluation, and
recommendation of applications for
financial assistance under the National
Foundation on the Arts and the
Humanities Act of 1965.
DATES: See SUPPLEMENTARY INFORMATION
for meeting dates. The meetings will
open at 8:30 a.m. and will adjourn by
5:00 p.m. on the dates specified below.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Voyatzis, Committee
Management Officer, 400 7th Street SW,
Room 4060, Washington, DC 20506;
(202) 606–8322; evoyatzis@neh.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to section 10(a)(2) of the Federal
Advisory Committee Act (5 U.S.C.
App.), notice is hereby given of the
following meetings:
SUMMARY:
1. Date: September 1, 2022
This video meeting will discuss
applications on the topic of U.S.
History, for the Digital Projects for the
Public: Prototyping Grants program,
submitted to the Division of Public
Programs.
E:\FR\FM\12AUN1.SGM
12AUN1
]]>Agencies
[Federal Register Volume 87, Number 155 (Friday, August 12, 2022)]
[Notices]
[Pages 49888-49889]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17361]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1065]
Importer of Controlled Substances Application: Galephar
Pharmaceutical Research, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Galephar Pharmaceutical Research, Inc. has applied to be
registered as an importer of basic class(es) of controlled
substance(s). Refer to Supplementary Information listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
September 12, 2022. Such persons may also file a written request for a
hearing on the application on or before September 12, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on July 28, 2022, Galephar Pharmaceutical Research,
Inc., 100 Carr 198 Industrial Park, Juncos, Puerto Rico 00777-3873,
applied to be registered as
[[Page 49889]]
an importer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Hydromorphone.......................... 9150 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
finished dosage form for analytical purpose only. No other activity for
this drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of Food and Drug
Administration-approved or non-approved finished dosage forms for
commercial sale.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-17361 Filed 8-11-22; 8:45 am]
BILLING CODE P
